A novel strategy for the next generation raav gene therapy and vaccine vector production

Active Grant Awarded

Award ID
R43AI197694
Recipient
Awarding agency
Obligated
$300,000

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 12% complete
Place of performance
Ames, IA 50014, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases awarded Grant R43AI197694 to Neovaxsyn Inc. (UEI EHMTBALCKFE8) on Aug 27, 2026, with $300,000 obligated under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will design, generate, and evaluate ONEBACMID, a baculoviral system built to express all factors necessary for recombinant adeno-associated virus (rAAV) generation, so that rAAV assembles in a mammalian environment. The project aims to improve rAAV quality and yield relative to the HEK293 and recombinant baculovirus production methods now in use, and the approach will be validated using HIV-1 envelope glycoprotein antigens for vaccine development. The award runs through Aug 31, 2028, and performance is located in Ames, IA 50014, USA. The assistance type is a grant. The parent program supports institutions and individuals in establishing, expanding, and improving biomedical research and research training in infectious and related diseases.

Description

Abstract
Despite the commercial availability of recombinant adeno-associated virus (RAAV) vectors for gene delivery, significant opportunities remain to improve RAAV quality and enhance their success in biomedical applications. A therapeutic viral vector requires rigorous optimization of critical quality attributes (CQAS) and high-titer production to meet dosage requirements for large-animal studies and human clinical trials. In this project, we aim to design, generate, and evaluate a novel RAAV production system optimized for mammalian applications, both in terms of quality and yield. Currently, two major RAAV production methods exist: (1) mammalian HEK293-based suspension cell culture, which relies on CO-transfection with two or three plasmids expressing essential protein factors; and (2) recombinant baculovirus (RBV)- mediated production, where insect SF9 suspension cells express AAV REP-cap and the gene of interest (GOI) separately. While the RBV method achieves high yields, IT often lacks proper post-translational modifications essential for functional gene expression in mammalian systems. In contrast, the HEK293 system produces properly modified RAAV but at insufficient purity and yield for therapeutic applications. To address these limitations, we propose a novel production strategy: the development of onebacmid, a baculoviral system designed to express all necessary factors for RAAV generation. Transducing one-RBV into mammalian cells would enable RAAV assembly in a humanized environment, thereby improving both quality and functionality. Our technical approach will be validated using HIV-1 envelope glycoprotein antigens for vaccine development. If successful, this strategy will significantly advance RAAV-based gene therapy and vaccine delivery by addressing a key bottleneck in next-generation viral vector development.

Quick answers

Who received award R43AI197694?

R43AI197694 was awarded to Neovaxsyn Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on August 27, 2026.

How much is award R43AI197694 worth?

$300,000 has been obligated on R43AI197694.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award